ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Renal"

  • Abstract Number: 1518 • ACR Convergence 2024

    Predictive Value of Chronic Histologic Changes in Lupus Nephritis

    Maria Cuellar-Gutierrez1, Jaime Flores Gouyonnet1, Gabriel Figueroa-Parra2, Marta Casal Moura1, Fernando C. Fervenza1, Andrew C. Hanson3, Cynthia Crowson1, Sanjeev Sethi1 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Mayo Clinic, Rochester

    Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…
  • Abstract Number: 2658 • ACR Convergence 2024

    Hypovitaminosis D in Lupus Nephitis

    Alicia Yupe1, Emma Puron Gonzalez2, Esteban Salatino3, Jessica Santana4, Montserrat Ochoa4, Rosa Elena Cervantes-Ramirez5, Eli Marisol Saldaña6, gabriel Calderon7, Brissia Ceniceros8, Ulices de la Cruz9, Monica Meza10 and Sergio Cerpa Cruz6, 1Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala., Guatemala, Guatemala, 2UDEM/ITESM, San Pedro Garza Garcia, Mexico, 3Faculty of Medical Sciences, Universidad de San Carlos de Guatemala., Guatemala, GU, 4Hospital Civil "Fray Antonio Alcalde", Guadalajara, Mexico, 5Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico, Distrito Federal, Mexico, 6Hospital Civil de Guadalajara, Guadalajara, Mexico, 7Hospital Civil de Guadalajara, Monterrey, Mexico, 8Hospital Civil de Guadalajara, Torreón, Coahuila de Zaragoza, Mexico, 9Hospital Civil "Fray Antonio Alcalde", Guadalajara, 10Centro Universitario de Ciencias de la SAlud, Guadalajara

    Background/Purpose: The prevalence of vitamin D deficiency is higher in patients with systemic lupus erythematosus (SLE) compared to the healthy population, and recent studies have…
  • Abstract Number: 0121 • ACR Convergence 2024

    Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers

    Liala Moschetti1, Savino Sciascia2, Micaela Fredi3, Mattia Zappa4, Massimo Radin5, Ilaria Cavazzana3, Stefania Affatato6, Cecilia Nalli7, Laura Andreoli8, Federico Alberici9, Franco Franceschini1, Dario Roccatello10 and Angela Tincani11, 1Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 2University of Turin, Torino, Turin, Italy, 3Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, ERN ReCONNET; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, 4Nephrology Unit and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, 5University of Turin, Turin, Italy, 6Nephrology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8University of Brescia, Brescia, Italy, 9Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, 10Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) and Department of Clinical and Biological Sciences; San Giovanni Bosco Hospital and University of Turin, Italy, Turin, Italy, 11ASST Spedali Civili-University of Brescia, Brescia, Italy

    Background/Purpose: Antiphospholipid antibodies nephropathy (aPL-N) is defined by thrombotic microangiopathy (TMA) early lesions and late lesions such fibro-intimal hyperplasia with luminal obliteration/organized thrombi, fibrous arterial/arteriolar…
  • Abstract Number: 1521 • ACR Convergence 2024

    Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States

    Aakash Patel1, Baijun Zhou2, Hyon K. Choi3 and April Jorge1, 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
  • Abstract Number: 0638 • ACR Convergence 2024

    Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response

    Ranjan Gupta1, Sonam Rajput2, Jayanth Kumar2 and Dipendra K Mitra2, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2All India Institute of Medical Sciences, New Delhi, New Delhi, India

    Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
  • Abstract Number: 1546 • ACR Convergence 2024

    Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA

    Anisha M. Patel1, Carmen Ng1, Lisa Lindsay1, Zhiyu Xia2, William F. Pendergraft III3 and Maria Dall'Era4, 1Genentech, Inc., South San Francisco, 2Genentech, Inc., Sou, 3Genentech, Inc., Chapel Hill, NC, 4UCSF, Corte Madera, CA

    Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
  • Abstract Number: 0651 • ACR Convergence 2024

    Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis

    Jung-Min Shin1, Jiyoung Lee2, Hye-Soon Lee3, Sang-Cheol Bae3 and So-Young Bang3, 1Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, 2Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

    Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
  • Abstract Number: 1566 • ACR Convergence 2024

    Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study

    Sumbal Wajid1, Lee Shapiro2, Virginia Steen3, Robyn Domsic4, Paul J. Feustel5 and Swati Mehta6, 1Albany Medical Center, Albany, NY, 2Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, 3Georgetown University School of Medicine, Washington, DC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, 6Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
  • Abstract Number: 0659 • ACR Convergence 2024

    Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

    Richard Furie1, Jorge A. Ross Terres2, Elsa Martins3, Imran Hassan4, Thomas Schindler3, Jay Garg5, William F. Pendergraft III6, Ana Malvar7 and Brad Rovin8, 1Northwell Health, Manhasset, NY, 2Genentech, Inc,, San Francisco, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Inc., Chapel Hill, NC, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8The Ohio State University, Columbus, OH

    Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
  • Abstract Number: 1569 • ACR Convergence 2024

    Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories

    Katya Dolnikov1, Kochava Toledano1, Marius Braun2, Doron Markovits1, Sami Giryes1, Yonit Tavor1, Alexandra Balbir-Gurman3 and Yolanda Braun Moscovici1, 1Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, HAIFA, Israel, 2Liver Insitute, Beilinson Hospital, Petach Tikva, Petach Tikva, Israel, 3Rheumatology Institute, Rambam Health Care Campus and The Rappaport Faculty of |Medicine, Technion, Haifa, Israel

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication that occurs in a minority of patients, particularly those with diffuse cutaneous systemic sclerosis ( SSc).…
  • Abstract Number: 0701 • ACR Convergence 2024

    Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study

    Aïcha Kante1, Paul Legendre2, Bérangère Joly3, bertrand Dunogue4, Alexandre Hertig5, Benjamin Terrier6, Elodie Massolin7, Felix Ackermann8, Luc Mouthon4, Jean Guibourdenche9 and Benjamin Chaigne10, 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 2Service immunologie clinique, Centre hospitalier du Mans, Le Mans, France, Le Mans, 3Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris (APHP.Nord), Université Paris Cité, Paris, Ile-de-France, France, 4Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 5Department of Nephrology, Hôpital Foch, Suresnes, France, Suresnes, Ile-de-France, France, 6Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 7UF d'Hormonologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, Paris, Ile-de-France, France, 8Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, 9APHP-CUP, Hôpital Cochin, F-75014 Paris, Université Paris Cité, Paris, Ile-de-France, France, 10Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France

    Background/Purpose: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Few biomarkers are available to predict…
  • Abstract Number: 1642 • ACR Convergence 2024

    A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis

    Andrea Fava1, Andrew Concoff2, Tyler O'Malley3, Sepehr Taghavi4, Touba Warsi4, Sudha Kumar4, Christine Schleif4 and Michelle Petri5, 1Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Vista, CA, 4Exagen, Carlsbad, CA, 5Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
  • Abstract Number: 0708 • ACR Convergence 2024

    Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis

    Vangala Adarsh1, dihowm Fatma1, Eyerusalem Akpan2, Meredith Keller2, Maheswari Muruganandam2, N. Suzanne Emil2, Frank O'Sullivan3, Roderick Fields2 and wilmer sibbitt1, 1UNM, Albuquerque, NM, 2University of New Mexico, Albuquerque, NM, 3University of New Mexico School of Medicine, Albuquerque, NM

    Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
  • Abstract Number: 1683 • ACR Convergence 2024

    68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis

    Shuyi Yu, Zetao Ding, Haoyu Pan, Jinyi Qian, Zhixia Yang, Xiaohan Wei, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)

    Background/Purpose: To evaluate the feasibility of using fibroblast activating protein inhibitor (FAPI) PET imaging as a molecular tracer and non-invasive tool for assessing renal tubulointerstitial…
  • Abstract Number: 0719 • ACR Convergence 2024

    Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease

    Joanna El Hajj1, Jennifer Waller1, Yagni Patel1, Wendy Bollag1, Stephanie Baer2 and Rachel Elam3, 1Augusta University, Augusta, GA, 2VA Augusta Healthcare System, Augusta, GA, 3Augusta University, Evans, GA

    Background/Purpose: End-stage renal disease (ESRD) secondary to vasculitis is linked to a higher risk of vertebral fractures compared to other causes of ESRD. It remains…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology